Kula Investments’s TG Therapeutics TGTX Stock Holding History

Kula Investments’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-28,890	Closed	-$342K	–	844
2022 Q4	$342K	Buy	+28,890	New	+$210K	0.1%	339

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kula Investments's TGTX Position: Q1 2023 in Review

Kula Investments sold out of TG Therapeutics (TGTX) in Q1 2023, closing a stake of 28,890 shares — an estimated $342K sold.

Kula Investments first reported a position in TGTX in Q4 2022 and held it in 1 quarter. The position peaked at $342K in Q4 2022. 214 funds tracked by Wall St. Rank hold TGTX as of Q1 2023.

Kula Investments reported no remaining TG Therapeutics position as of Q1 2023 after selling out during the quarter.
Kula Investments sold 28,890 TG Therapeutics shares in Q1 2023, an estimated $342K.
Kula Investments first reported a position in TG Therapeutics in Q4 2022 and held it in 1 quarter.
Kula Investments's TG Therapeutics position peaked at $342K in Q4 2022.
214 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.